Guillermo Garcia-Manero

Trials

Studies that name Guillermo Garcia-Manero as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:10 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT06641414 · Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

  Ascentage Pharma Group Inc. · recruiting · Higher-risk Myelodysplastic Syndrome · study chair
• Ph2
  NCT06113302 · A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

  M.D. Anderson Cancer Center · active not recruiting · Myelodysplastic Syndromes · principal investigator
• Ph1/Ph2
  NCT05732103 · A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

  Chordia Therapeutics, Inc. · recruiting · Acute Myeloid Leukemia, Myelodysplastic Syndromes · principal investigator
• Ph1/Ph2
  NCT04655755 · Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  M.D. Anderson Cancer Center · active not recruiting · Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome · principal investigator
• Ph1/Ph2
  NCT04550442 · Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  M.D. Anderson Cancer Center · terminated · Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia · principal investigator
• Ph2
  NCT04239157 · A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

  M.D. Anderson Cancer Center · recruiting · Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia · principal investigator
• Ph1/Ph2
  NCT04160052 · Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

  M.D. Anderson Cancer Center · terminated · Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome · principal investigator
• Ph3
  NCT03151408 · An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

  Helsinn Healthcare SA · terminated · Acute Myeloid Leukemia · study chair
• Ph2
  NCT03094637 · Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

  M.D. Anderson Cancer Center · unknown · High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome · principal investigator
• Ph2
  NCT02599649 · Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

  M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
• Ph2
  NCT02530463 · Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

  M.D. Anderson Cancer Center · active not recruiting · Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome · principal investigator
• N/A
  NCT02378701 · Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

  M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
• Ph1/Ph2
  NCT02363491 · A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

  Opsona Therapeutics Ltd. · completed · Myelodysplastic Syndrome
• Ph2
  NCT02269280 · Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

  M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
• Ph1/Ph2
  NCT02193958 · Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

  Fujifilm Pharmaceuticals U.S.A., Inc. · completed · AML, CMML, MDS · principal investigator
• Ph2
  NCT02131597 · Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes

  M.D. Anderson Cancer Center · completed · High Risk Myelodysplastic Syndrome · principal investigator
• Ph2
  NCT01993641 · Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

  Helsinn Healthcare SA · completed · Myelodysplastic Syndrome, MDS · principal investigator
• Ph2
  NCT01912274 · Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

  Helsinn Healthcare SA · completed · Acute Myeloid Leukemia · principal investigator
• Ph1
  NCT01895842 · Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

  M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
• Ph2
  NCT01891968 · Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

  M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
• Ph2
  NCT01873703 · Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

  Helsinn Healthcare SA · completed · Myelodysplastic Syndrome · principal investigator
• Ph3
  NCT01802333 · Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

  National Cancer Institute (NCI) · completed · Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia · principal investigator
• Ph1
  NCT01684150 · A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving

  Epizyme, Inc. · completed · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome · principal investigator
• Ph2
  NCT01444742 · Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

  M.D. Anderson Cancer Center · completed · Leukemia, Myeloproliferative Diseases · principal investigator
• Ph2
  NCT01436084 · SB1518 for Patients With Myelodysplastic Syndrome (MDS)

  M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
• Ph1/Ph2
  NCT01038635 · 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

  M.D. Anderson Cancer Center · completed · Leukemia · study chair
• Ph2
  NCT00948064 · Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

  M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
• Ph2
  NCT00939159 · Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

  M.D. Anderson Cancer Center · terminated · Myelodysplastic Syndrome · study chair
• Ph2
  NCT00903760 · Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

  M.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome · principal investigator
• Ph2
  NCT00893997 · PR1 Vaccination in Myelodysplastic Syndrome (MDS)

  M.D. Anderson Cancer Center · terminated · Leukemia, Myelodysplastic Syndrome · principal investigator
• Ph1
  NCT00741234 · A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

  S*BIO · completed · Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome · principal investigator
• Ph2
  NCT00656617 · Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

  M.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) · study chair
• Ph2
  NCT00382590 · Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

  M.D. Anderson Cancer Center · completed · Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia · principal investigator
• Ph1
  NCT00349596 · A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

  M.D. Anderson Cancer Center · completed · Acute Lymphocytic Leukemia · principal investigator
• Ph1
  NCT00331513 · Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

  National Cancer Institute (NCI) · completed · Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) · principal investigator
• Ph2
  NCT00326170 · Phase II 5-Azacytidine Plus VPA Plus ATRA

  M.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome, Acute Myelogenous Leukemia · principal investigator
• Ph1/Ph2
  NCT00075010 · Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

  M.D. Anderson Cancer Center · completed · Leukemia, Myelodysplastic Syndromes · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Phase I study of 5-aza-2?-deoxycitidine in acute lymphocytic leukemia
  R21CA126457 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2007 to 2008 · $292,600 awarded in 2008
  Same name and institution; not confirmed by an ID
• Cell Cycle Controlling Genes in Adult Acute Lymphoma
  R21CA100067 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2004 to 2005 · $135,900 awarded in 2005
  Same name and institution; not confirmed by an ID
• Phase1/11 study of 5-aza-2'-deoxycytidine and valproic *
  R21CA105771 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2004 to 2005 · $309,550 awarded in 2005
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• SWOG Network Group Operations Center of the NCTN
  U10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026
  Named on NCT01802333
• Southwest Oncology Group Treatment Grant
  U10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES D. BLANKE · fiscal years 1985 to 2013
  Named on NCT01802333
• Phase I Studies of Targeted Anti-Cancer Therapies
  U01CA062461 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI James C Yao · fiscal years 1994 to 2013
  Named on NCT00331513